Relapse and Prognosis of Non-Muscle Invasive Bladder Cancer After Combined HOLRBT with Sunitinib and TGC Perfusion Chemotherapy

Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.

https://www.liebertpub.com/doi/abs/10.1089/cbr.2019.3455?ai=sx&mi=o0fy&af=R

Source: Cancer Biotherapy and Radiopharmaceuticals - April 30, 2020 Category: Cancer & Oncology Authors: Songjiang Li Kai Zhao Yueli Jin Zheng Ma Rong Sun Wei Zhao Huilei Yan Yuqiao Li Source Type: research

More News: Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Perfusion